Antithrombin III Level, Fibrinogen Level, and Platelet Count Changes With Adjuvant Tamoxifen Therapy

Archives of Internal Medicine

Volumn 152, Issue 2, 1992, Pages 317-320

  Love, Richard R ^a   Surawicz, Tanya S ^a   Williams, Eliot C ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; FIBRINOGEN; PLACEBO; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; RISK; THROMBOCYTE COUNT; THROMBOPHLEBITIS;

ANTITHROMBIN III; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; HUMAN; PLATELET COUNT; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; THROMBOPHLEBITIS;

EID: 0026519891     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1992.00400140065015     Document Type: Article

References (21)

1. Early Breast Cancer Trialists’ Collaborative Group. The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319:1681-1692.
2. Love RR. Tamoxifen therapy in primary breast cancer: biology, efficacy and side effects. J Clin Oncol. 1989;7:803-815.
3. Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Lancet. 1987;2:171-175.
4. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor—positive tumors. N Engl J Med. 1989;320:479-484.
5. Fisher B, Brown A, Wolmark M, Redmond C, Wickerham DL, Wittliff J. Prolonging tamoxifen therapy for primary breast cancer. Ann Intern Med. 1987;106:649-654.
6. Falkson HC, Gray R, Wolberg WH, Falkson G. Adjuvant therapy of postmenopausal women with breast cancer: an ECOG phase III study. Proc Am Soc Clin Oncol. 1989;8:19. Abstract.
7. Jordan VC. Long term tamoxifen therapy for breast cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia, Pa: JB Lippincott; 1989:179-192.
8. Enck RE, Rios CM. Tamoxifen treatment of metastatic breast cancer and anti-thrombin III levels. Cancer. 1984;53:2607-2609.
9. Rieche K. Die Beeinflussung des funktionellen Antithrombin III im Plasma durch Tamoxifen und Aminoglutethamide. Krebsmedizin. 1986;7:60-63.
10. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat. 1988;12:307-310.
11. Auger MJ, Mackie MJ. Effects of tamoxifen on blood coagulation. Cancer. 1988;61:1316-1319.
12. Jordan VC, Fritz NF, Tormey DC. Long term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III. Cancer Res. 1987;47:4517-4519.
13. Powles TJ, Hardy SE, Ashley GM, Farrington GM, Cosgrove D, Davey JB. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989;60:126-131.
14. Love RR. The Wisconsin Tamoxifen Study: toxicity in node-negative postmenopausal women. Cancer Invest. 1988;6:601-605.
15. Love RR, Newcomb PA, Wiebe DA, et al. Lipid and lipoprotein effects of tamoxifen therapy in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990;82:1327-1332.
16. Prochownik EV. Molecular genetics of inherited antithrombin III deficiencies. Am J Med. 1989;87(suppl 38):153-185.
17. Tormey DC, Simon RM, Lippman ME, Bull JM, Myer CE. Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat Rep. 1976;60:1451-1459.
18. Tormey DC, Lippman ME, Edwards BK, Cassidy JG. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med. 1983;98:139-144.
19. Wilhelmsen L, Svärdsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
20. Meade TX, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park heart study. Lancet. 1986;2:5330-5337.
21. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA. 1987;258:1183-1186.